Status:
ACTIVE_NOT_RECRUITING
Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
End-stage Liver Diseases
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
There is a rise in the prevalence of end-stage liver disease during the last decade. End-stage liver disease has become one of the leading causes of death in Western countries. Liver transplantation i...
Detailed Description
Twenty-two subjects with end-stage liver disease attending the Department of Gastroenterology of the General Hospital of the Northern Theatre of Operations are expected to be enrolled over a period of...
Eligibility Criteria
Inclusion
- 18-80 years old
- End-stage liver disease
- Sign informed consent
Exclusion
- Tumours of the liver or other organs
- Liver transplantation recipients
- Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
- Other diseases that may seriously affect the survival
- Human immunodeficiency syndrome
- Interferon or glucocorticoid therapy within 1 year
- Treated for mental illness
- Participation in other clinical trials within 30 days
- Pregnant or breastfeeding subjects
- Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
- Other circumstances that are unsuitable for participation in this study
Key Trial Info
Start Date :
November 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06167473
Start Date
November 28 2023
End Date
December 1 2025
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110840